J Clin Oncol (Meeting Abstracts) 2008, 26: 4000. 26. Van Cutsem E, Lang I, D’Haens G, Moiseyenko V, Zaluski J, Folprecht G, Tejpar S, Kisker O, Stroh C, Rougier P: KRAS status

and efficacy in the first-line treatment of patients with metastatic Caspase Inhibitor VI manufacturer colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol (Meeting Abstracts) 2008, 26: 2. 27. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26: 1626–1634.CrossRefPubMed 28. Betensky RA, Louis CRM1 inhibitor DN, Cairncross JG: Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 2002, 20: 2495–2499.CrossRefPubMed 29. Lagakos SW: The challenge of subgroup analyses – reporting without distorting. N Engl J Med 2006, 354: 1667–1669.CrossRefPubMed

30. Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G: Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess 2001, 5: 1–56.PubMed 31. Altman DG, Matthews JN: Statistics notes. Interaction 1: Heterogeneity of effects. Bmj 1996, 313: 486.PubMed 32. Hoering A, Leblanc M, Crowley JJ: Randomized phase III clinical trial designs for targeted agents. Clin Cancer Res 2008, 14: 4358–4367.CrossRefPubMed 33. Carter RE, Woolson RF: Statistical design considerations for pilot studies transitioning therapies AZD1080 price from the bench to the bedside. J Transl Med 2004, 2: 37.CrossRefPubMed 34. Bagnato Baf-A1 A, Natali PG: Endothelin receptors as novel targets in tumor therapy. J Transl Med 2004, 2: 16.CrossRefPubMed Competing interests The authors declare that they have no competing interests. Authors’ contributions EB, MDM and MM planned and conceived the review; EB, MDM, FC and MM carried out all

available evidences; EB, MDM, FC, DG, FC, PC, and MM drafted the manuscript; all authors read and approved the final manuscript.”
“Background Gallbladder cancer is a relatively rare but terminal malignancy occurring predominantly in elderly women. It accounts for nearly two-thirds of biliary tract cancers, making it the most common primary biliary cancer and the fifth most common cancer of the gastrointestinal tract [1, 2]. More than 85% of gallbladder cancers belong to adenocarcinomas that are often well or moderately differentiated, and the remaining 15% are squamous, adenosquamous or undifferentiated carcinomas. Surgery is the only recommended treatment currently available. However, more than 70% of cases are un-resectable due to local invasion into critical structures or metastasis beyond regional confines.